A Phase 3 interventional study of EYP-1901 and Aflibercept (2.0 mg) in Diabetic Macular Edema, DME and Diabetic Macular Edema (DME), sponsored by EyePoint Pharmaceuticals, Inc.. Active, not recruiting at 73 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by EyePoint Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 33 under way, 11 of them phase 3. Macular Edema · United States.
Among the 276 studies in Macular Edema with a site in United States, this one is the 51st largest by planned enrollment of the 244 interventional ones that give a count, is one of 10 that started in 2026, is one of 50 in phase 3, reaches primary completion later than 22 of the 32 other live ones, and was the 270th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Israel and 1 more country
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 1 more country
Ages 18+
Kodiak Sciences Inc · Sites in United States, Argentina
Ages 18+
Massachusetts Eye and Ear Infirmary · Sites in United States
Ages 18+
Boehringer Ingelheim · Sites in United States, Puerto Rico
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
276 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 74 · Phase 2 101 · Phase 3 57 · Phase 4 33
First in 1992; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 45 across the 244 interventional studies, 60 across the 30 observational. Of the 222 that completed or were terminated, 130 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
133 of 276 have an industry lead sponsor. The 10 most frequent:
EyePoint Pharmaceuticals, Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 8 (73%) have results posted.
EyePoint Pharmaceuticals, Inc. has 3 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
11 of the studies in Macular Edema with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06957080Phase 3EyeBiotech Ltd.A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME | 2027-01-11 |
| NCT06996080Phase 3Kodiak Sciences IncA Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | 2027-02 |
| NCT06990399Phase 3Kodiak Sciences IncA Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK | 2027-04 |
| NCT04108156Phase 3Hoffmann-La RocheA Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME | 2027-07-20 |
| NCT07449923Phase 3EyePoint Pharmaceuticals, Inc.CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | 2027-10 |
Add all 11 to your calendar (.ics) → With an account.
Among the 276 studies in Macular Edema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
EYP-1901
Drug: EYP-1901
Drug: Aflibercept (2.0 mg)
Intravitreal Injection
Intravitreal Injection
Average change in best corrected visual acuity (BCVA)
BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) letter score change from Baseline to the average of Weeks 52 and 56
Time frame: Weeks 52 and 56
Rate of injection burden
Time frame: Week 56
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Oct 2027, 20 months after the start.
Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's planned 20 months is below that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorolanib
EyePoint Pharmaceuticals, Inc.